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Abstract: Two unusual pyridones, trichodin A (1) and trichodin B (2), together with the 
known compound, pyridoxatin (3), were extracted from mycelia and culture broth of the 
marine fungus, Trichoderma sp. strain MF106 isolated from the Greenland Seas. The 
structures of the new compounds were characterized as an intramolecular cyclization of  
a pyridine basic backbone with a phenyl group. The structure and relative configuration of 
the new compounds were established by spectroscopic means. The new compound 1 and the 
known compound 3 showed antibiotic activities against the clinically relevant microorganism, 
Staphylococcus epidermidis, with IC50 values of 24 μM and 4 μM, respectively. 
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1. Introduction 
Marine habitats provide unique ecological niches for fungi, which are of great interest as promising 
sources of new biologically active products. Since marine fungi live in a biologically competitive 
environment with unique physical and chemical parameters, such as pH, temperature, pressure, 
oxygen, light, nutrients and salinity, the chemical diversity of the secondary metabolites and their 
range of applications from marine fungi is high [1–7]. Pyridone alkaloids characterized by a pyridine 
and a mono sesquiterpene in their structures are important microbial secondary metabolites [8]. 
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Pyridoxatin 3, a potent free radical scavenger with activity 20 times as active as vitamin E, was first 
reported by Teshima et al. [9]. It has been synthesized by Snider’s group, because of the structural 
uniqueness and interesting bioactivity [10]. 8-Methyl pyridoxatin was reported to induce erythropoietin 
in human cells [11]. Fungi of the genus, Trichoderma (teleomorph Hypocrea, class Sordariomycetes, 
order Hypocreales) are widespread in both terrestrial and marine environments. The genus comprises 
approximately 150 species [12]. They are frequently found on decaying wood and in soil, as well as in 
marine sediments, marine sponges and mangrove forests [13]. Members of Trichoderma living in the 
rhizosphere of plants are seen as opportunistic plant symbionts and are beginning to be used in 
reasonably large quantities in plant agriculture, both for disease control and yield increases. The ability 
of Trichoderma sp. strains to parasitize or even prey on other fungi is widely used for the biological 
control of phytopathogenic fungi. Studies of mycoparasitism also have demonstrated that these  
fungi produce a rich mixture of antifungal enzymes, including chitinases and β-1,3 glucanases [14]. 
Trichoderma longibrachiatum is known as an opportunistic pathogen of immunocompromised 
mammals, including humans, and some species are common indoor contaminants [15,16]. Marine 
representatives of the genus Trichoderma produce a variety of bioactive metabolites [17], which include 
the antimycobacterial aminolipopeptide trichoderins [18], the antifungal, trichodermaketone A [13], the 
cytotoxic dipeptide, trichodermamide B [19], as well as antibacterial tetrahydroanthraquinone and 
xanthone derivatives [20]. 
In this study, two new pyridones were identified in cultures of the marine fungal strain, MF106. 
2. Results and Discussion 
2.1. Identification of Strain MF106 
Colonies on WSP30 medium grew slowly and attained a diameter of 16 mm within seven days of 
incubation at 26 °C. They were pale white to greenish-white with a yellow back side (Figure 1). 
Conidia were produced only sparsely on WSP medium, as well as on further media (data not shown). 
The conidiophores were irregularly branched, divergent, bearing flask-shaped phialides with distinct 
necks. The conidia were colorless, rough-walled, ellipsoid-cylindrical, 4.5–5.0 × 2.0–2.2 µm in size 
and held in a mucilaginous drop at the end of each phialide (Figure 2). Strain MF106 showed 
morphological features typical of Trichoderma sp. Since the genus, Trichoderma, contains about  
200 species [21], which are very difficult to differentiate by morphological criteria, it was not possible 
to classify strain MF106 on the species level. 
2.2. Structural Elucidation 
Organic extracts of the cultured mycelia and broth of strain MF106 were subjected to repeated 
column chromatography on preparative HPLC (C18), to afford the two new compounds, 1 and 2, and 
the known pyridoxine (3) [9] (Figure 3). Pyridoxatin (3) was the major component, whereas 
Compounds 1 and 2 were isolated as minor components. 
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Figure 1. Colony of Trichoderma sp. strain MF106 on WSP medium. 
 
Figure 2. Scanning electron micrographs of Trichoderma sp. strain MF106, showing 
conidiophores with phialides producing rough-walled conidia at the end. 
 
Figure 3. The structures of Compounds 1–3. 
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Compound 1 was obtained as a brown powder. The HR-TOF-MS exhibited an ion peak at  
m/z 362.1751 [M + Na]
+
 (calcd. 362.1727), indicating that the molecular formula was C21H25NO3 with 
ten degrees of unsaturation. The IR spectrum revealed the presence of hydroxy groups and an aromatic 
ring characterized by absorptions at a νmax of 3105 and 1614 cm
−1
, respectively. The phenolic nature of 
the compound was indicated by its characteristic color reactions (FeCl3: purple; phosphomolybdic acid 
reagent: deep blue). 
The 
13
C NMR spectrum showed the presence of 14 signals for pyridoxatin, including the pyridone 
skeleton and a cyclohexane substructure, with the remaining four resonances corresponding to a  
1,4-disubstituted aromatic moiety. The presence of a 3,4,5-trisubstituted pyridin-2(1H)-one was 
supported by both 
1
H and 
13
C NMR data. The only pyridone proton signal at δH 7.13 showed a doublet 
with a small coupling constant of 0.5 Hz, attributing this proton to be adjacent to the NH of the 
pyridone ring and positioning a hydrogen on the pyridone nitrogen instead of a N-OH group in 
pyridoxatin (3). The diagnostic HMBC correlation from the pyridone doublet at δH 7.13 (d, J = 0.5 Hz, 
H-6) to the carbonyl at δC 165.9 (s, C-2) revealed a pyridin-2(1H)-one. The upfield region of the  
1
H 
1
H COSY spectrum of 1 demonstrated the presence of one proton spin systems connecting all the 
alkylic protons and consisting of four methylene protons, four methine protons, one oxygenated 
methine and three groups of methyl protons. The methine proton triplet at δH 2.29 (d, J = 10.1 Hz, H-7) 
coupled to the methine proton multiplet at δH 1.75 (m, H-12), which, in turn, coupled to a methyl 
proton doublet at δH 1.15 (d, J = 6.8, Me-16) and one methylene proton at δH 1.07 (dd, J = 24.8,  
11.8 Hz, H-11α). This methylene proton was also coupled to its geminal partner at δH 1.80 (br d,  
J = 13.2 Hz, H-11β) and to the methine proton at δH 1.70 (m, H-10), which, in turn, coupled to the 
methyl doublets at δH 1.02 (d, J = 6.6 Hz, Me-15) and a pair of most upfield methylene protons at  
δH 0.89 (dd, J = 23.9, 12.1 Hz, H-9α) and a proton at δH 1.89 (br d, J = 14.9 Hz, H-9β), respectively. 
The proton signal at δH 1.54 (ddd, J = 23.9, 10.2, 2.6 Hz, H-8) showed cross peaks with methylene 
protons of H-9, the methine proton signal of H-7 and the oxymethine proton at δH 3.72 (m, H-13) 
coupled with methyl doublets at δH 1.31 (d, J = 6.3 Hz, Me-14). A sequence of cyclohexane 
substructure of H-7/H-8/H-92/H-10/H-112/H-12/H-7 with two Me groups at C-10 and C-12 was 
deduced from the above 
1
H 
1
H COSY analyses (Figure 4, Supplementary Information, Figures S4 and S5). 
Figure 4. Key 
1
H 
1
H COSY and HMBC correlations of Compound 1. 
N
H
O
O
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The NMR data (Table 1) in the upfield region of 1 were similar to those of the known pyridone 
compound, pyridoxatin (3), isolated from the same fungus, except that a doublet methyl protons signal 
(δH 1.31, (d, J = 6.3 Hz), Me-14) and oxygenated methine proton at δH 3.72 (m, H-13) were added  
in 1 [9]. In the downfield region of the NMR spectra of 1, the terminal double bond signals were 
missing, when compared to the NMR data of pyridoxatin. These differences suggested that the 
terminal double bond at the C-8 of the cyclohexane ring transformed to a –OCH-CH3 unit, which was 
confirmed by the observation of HMBC correlations from Me-14 to C-8 and from methylene H-9 to 
the oxygenated C-13. The connectivity between the pyridin-2(1H)-one unit and the cyclohexane 
substructure were realized by detailed analyses of 
1
H–13C long-range correlations. The HMBC 
correlations from the methine proton triplet at δH 2.29 (d, J = 10.1 Hz, H-7) in the cyclohexane ring to 
the carbonyl carbon signal at δC 169.9 (s, C-2) and the carbon signal at δC 113.3 (s, C-3) in the 
pyridone unit indicated that the cyclohexane was linked at C-3. The oxymethine proton at δH 3.72  
(m, H-13) exhibited a diagnostic long-range correlation with an aromatic carbon signal at δC 165.9  
(s, C-4), revealing that an oxygen atom bridge was formed between C-4 at the pyridone unit and C-13 
at the side chain of the cyclohexane unit. It is suggested that the oxygen in the –OCH-CH3 unit 
mentioned is the same one in pyridin-2(1H)-one unit of pyridoxatin (3) that ends up incorporated into 
the ring in compound 1 (Figure 3). The analyses of 1D and 2D NMR data completed the elucidation of 
a condensed ring system of pyridine, pyran and cyclohexane (Figure 4). 
The formula indicated that six carbons remain to be assigned to the molecule of 1. When the 
downfield region of the NMR spectra of 1 is compared with that of pyridoxatin (3), two additional sets 
of equivalent aromatic protons at δH 7.25 (d, J = 8.8 Hz, H-18, H-22) and δH 6.80 (d, J = 8.8 Hz, H-19, 
H-21) and four aromatic carbons at δC 126.6 (s, C-17),131.3 (d, C-18/22), 115.9 (d, C-19/21) and 
157.9 (s, C-20) were observed, whereas one of the aromatic protons of the pyridone ring was absent 
(Table 1). The remaining four aromatic carbon and signals represented a para-substituted phenol, 
whose linkage position was assigned by the analyses of HMBC correlations. HMBC correlations from 
the only proton of H-6 at the pyridone unit to the aromatic C-17 and C-18/22 and from the equivalent 
aromatic protons of H-18/22 to the pyridone C-5 positioned the phenol at C-5. These 1D and 2D NMR 
analyses permitted the complete assignment of the planar structure of 1, as shown in Figure 3. The 
proton signal of H-7 exhibited a triplet with a coupling constant of 10.1 Hz, suggestive of a  
7,8-trans ring fusion between the pyran and cyclohexenyl rings. 
Two sets of 1,3-diaxial NOESY correlations were observed (Figure 5, Supplementary Information, 
Figures S10 and S11). The 1,3-diaxial NOESY cross peaks of H-7α/H-9α, H-7α/H-11α and  
H-9α/H-11α revealed a cyclohexenyl boat ring in Molecule 1. Additional 1,3-diaxial NOESY cross 
peaks of H-8β/H-12β and H-8β/H-10β indicated that two methyls at C-10 and C-12 were equatorial. 
The trans ring fusion between the pyran chair and cyclohexenyl boat rings were confirmed by the 
above 1,3-diaxial NOESY correlations. The proton signal of Me-14 showed NOESY correlations with 
H-8β and H-9β, assigning the Me-14 as β-oriented. This inference was confirmed by the diagnostic 
NOESY correlation of H-7α/H-13α. Thus, Compound 1 was elucidated as a new pyridone derivative. 
It is given the trivial name, trichodin A. 
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Table 1. NMR data for Compounds 1 (500 MHz), 2 and 3 (600 MHz) in CD3OD. 
Position 
1 2 3 
δC 
a, b
, type 
δH 
c
, multiplicities  
(J in Hz) 
δC 
a, b
, type 
δH 
c
, multiplicities  
(J in Hz) 
δC 
a, b
, type 
δH 
c
, multiplicities  
(J in Hz) 
2 165.9, C - 165.8, C - 160.4, C - 
3 113.0, C - 113.0, C - 114.7, C - 
4 165.9, C - 166.0, C - 164.0, C - 
5 117.6, C - 117.2, C - 99.0, CH 5.94, d (8.2) 
6 131.3, CH 7.13, d (0.5) 131.6, CH 7.15, s 132.8, CH 7.52, d (8.2) 
7 45.4, CH 2.29, t (10.1) 45.3, CH 2.26, t (10.1) 45.2, CH 2.46, t (10.8) 
8 50.9, CH 
1.54, ddd  
(23.9, 10.2, 2.6) 
50.9, CH 
1.53, ddd (24.0,  
10.2, 2.6) 
48.1, CH 3.00, m 
9α 38.5, CH2 
0.89, dd  
(23.9, 12.1) 
38.5, CH2 
0.89, dd  
(24.0, 12.0) 
43.6, CH2 1.73, m 
9β  1.89, br d (14.9) - 1.87. br d (12.2) - 0.89, m 
10 34.1 CH 1.70, m 34.1, CH 1.68, m 33.0, CH 1.61, m 
11α 47.1, CH2 
1.07, dd  
(24.8, 11.8) 
47.1, CH2 
1.06, dd  
(24.7, 11.8) 
45.9, CH2 1.71, m 
11β - 1.80, br d (13.2) - 1.78, br d (13.0) - 0.77, m 
12 41.9, CH 1.75, m 41.9, CH 1.71, m 33.0, CH 2.37, m 
13 79.7, CH 3.72, m 79.7, CH 3.68, m 144.7, CH 5.53, ddd (16.8, 10.0, 9.2) 
14 19.1, CH3 1.31, d (6.3) 19.1, CH3 1.28, d (6.2) 113.0, CH 
4.75, dd (16.5, 2.1),  
4.61 dd (10.0, 2.1) 
15 22.8, CH3 1.02, d (6.6) 22.8, CH3 0.99, d (6.4) 23.2, CH3 0.92, d (6.6) 
16 23.2, CH3 1.15, d (6.8) 23.2, CH3 1.12, d (6.7) 21.0, CH3 0.71, dd (6.7) 
17 126.6, C  129.3, C - - - 
18/22 131.3, CH 7.25, d (8.8) 131.2, CH 7.33, d (8.7) - - 
19/21 115.9, CH 6.80, d (8.8) 117.9, CH 7.13, d (8.7) - - 
20 157.9, C - 158.1, C - - - 
Ribose - - - - - - 
1 - - 102.4, CH 5.64, d (4.4) - - 
2 - - 73.4, CH 4.19, dd (6.4, 4.5) - - 
3 - - 71.2, CH 4.10, dd (6.5, 3.2) - - 
4 - - 87.5, CH 5.15, dd (7.0, 3.5) - - 
5a - - 63.2, CH2 3.65, dd (12.1, 4.0) - - 
5b - - - 3.71, dd (12.1, 3.4) - - 
a Recorded at 125 MHz; b carbon type inferred from DEPT (Distortionless Enhancement by Polarization Transfer) and 
HMQC (Heteronuclear Multiple Quantum Correlation) experiments; c recorded at 500 MHz. 
Compound 2 was isolated as a brown powder. The molecular formula was determined to be 
C26H33NO7 by analysis of the HR-TOF-MS ion peak at m/z 494.2131 [M + Na]
+
 (calcd. 494.2149). 
The IR spectrum suggested the presence of hydroxyl (3251 cm
−1
) and aromatic (1612 cm
−1
) groups. 
1
H 
and 
13
C NMR spectra showed signals in close agreement with those of Compound 1, except that the 
OH group was replaced by a sugar moiety. The diastereotopic nature of the protons in the 
1
H NMR of 
Compound 2 suggested that the introduction of the sugar moiety significantly hinders rotation around 
the aryl-pyridone bond. Analysis of the 1D and 2D NMR data and comparison with those of  
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Compound 1 led to identification of the structure of 2 as a glycosylated derivative of 1 with 
ribofuranose [22]. The glycosylated position in the aglycone was deduced to be at C-20 by HMBC 
experiments (Supplementary Information, Figures S18 and S19). The relative configuration of the 
aglycon of 2 was proved to be the same as compound 1 after detailed analysis of the proton coupling 
constants of 2.
 
The configuration of the glycosidic linkage of the ribofuranoside moiety in 2 was 
determined to be β on the basis of the J value (δH 5.64 (d, J = 4.4 Hz)) of the anomeric proton. 
Therefore, the structure of 2 was elucidated as a new ribofuranoside of 1, and given the trivial name, 
trichodin B. The assignment of the NMR signals of 2 is listed in Table 1. 
Figure 5. Key NOESY (nuclear Overhauser enhancement spectroscopy) correlations of 
Compound 1. 
 
2.3. Biological Activities 
Compound 1 showed moderate antibiotic activities against the Gram-positive Bacillus subtilis with 
an IC50 value of 27.05 ± 0.53 µM, Staphylococcus epidermidis with an IC50 value of 24.28 ± 3.90 µM, 
Staphylococcus aureus (MRSA) with an IC50 value >80 μM and the yeast, Candida albicans  
(IC50 value 25.38 ± 0.41 μM). No activity was observed against Trichophyton rubrum.  
While Compound 2 exhibited no antimicrobial effects against all test strains, Compound 3 was  
active against B. subtilis, S. epidermidis, Staphylococcus aureus (MRSA), C. albicans and 
Trichophyton rubrum with IC50 values of 5.28 ± 0.42 μM, 4.25 ± 0.81 μM, 4.40 ± 0.14 μM,  
26.25 ± 0.14 μM and 4.05 ± 1.28 μM, respectively. 
3. Experimental Section 
3.1. General Experimental Procedures 
Optical rotations were recorded on a Perkin Elmer 241 polarimeter. The IR spectra were run on  
a Perkin Elmer spectrometer with an ATR unit. 
1
H NMR (500 MHz) and 
13
C NMR (125 MHz) spectra 
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were measured at 25 °C on a Bruker AVANCE DRX 500 NMR spectrometer with TMS as the internal 
standard. The signals of the residual solvent protons and the solvent carbons were used as internal 
references (δH 3.31 ppm and δC 49.0 ppm for methanol-d4). High-resolution mass spectra were 
acquired on a benchtop time-of-flight spectrometer (micrOTOF II, Bruker Daltonics, Bremen, 
Germany) with positive electrospray ionization (ESI). 
Analytical reversed phase HPLC-DAD(UV)-MS experiments were performed using a C18 column 
(Phenomenex Onyx Monolithic C18, 100 × 3.00 mm) and applying an H2O/acetonitrile (ACN) gradient 
with 0.1% formic acid added to both solvents (gradient: 0 min 5% ACN, 4 min 60% ACN, 6 min  
100% ACN; flow: 2 mL/min) on a VWR Hitachi Elite LaChrom system with an L-2450 diode array 
detector, an L-2130 pump and an L-2200 autosampler. This HPLC system was coupled to an ESI-ion 
trap detector with positive ionization (Esquire 4000, Bruker Daltonics) for mass detection. 
The preparative HPLC was conducted with a VWR HPLC-UV system (VWR International LaPrep, 
VWR, Darmstadt, Germany) equipped with a pump (P110), a UV detector (P311), a Smartline 3900 
autosampler (Knauer, Berlin, Germany), a LABOCOL Vario-2000 fraction collector (LABOMATIC, 
Weil am Rhein, Germany) and a Phenomenx Gemini-NX column (C18, 10 μm, 110 Å, 100 × 50 mm). 
An H2O/acetonitrile (ACN) gradient with 0.1% formic acid added to both solvents was applied 
(gradient: 0 min 10% ACN with a flow of 40 mL/min; 0.5 min 10% ACN, 17 min 60% ACN, 22 min 
100% ACN, 26 min 10% ACN; flow: 100 mL/min). 
Semi-preparative HPLC was carried out using an HPLC-UV system (VWR Hitachi Elite  
LaChrom system, VWR, Darmstadt, Germany) consisting of an L-1230 pump, an L-2450 diode array 
detector, an L-2200 autosampler and a Phenomenex Luna column (Silica (2), 5 µm, 100 Å,  
250 × 10 mm), respectively. 
3.2. Isolation, Cultivation, Identification and Storage of the Producer Strain, MF106 
Strain MF106 was isolated from a Greenland Sea (Fram Strait) sample taken on the cruise  
FS “Polarstern” ARKTIS VIII/1 in June, 1991 [23], and cultured on WSP30 medium, a modified 
Wickerham-medium, which consisted of 1% glucose, 0.5% peptone, 0.3% yeast extract, 0.3% malt 
extract and 3% sodium chloride (pH = 6.8) [24]. The strain was stored at the Kultursammlung Mariner 
Pilze (KSMP-Kiel, Kiel, Germany) using two methods, liquid nitrogen and the Microbank System at  
−80 °C (MAST DIAGNOSTIKA, Reinfeld, Germany). 
The identification has been performed by morphological criteria using scanning electron 
microscopy. Colonies growing on WSP30 agar plates were cut in 1 cm² samples, transferred through 
an ethanol series (30%, 50%, 70%, 90%, 3 × 100%; each 15 min) and subsequently critical-point-dried 
in liquid carbon dioxide (Balzers CPD030, Oerlikon Balzers Coating Germany GmbH, Bingen am 
Rhein, Germany). Samples were sputter-coated with gold-palladium (Balzers SCD004, Oerlikon 
Balzers Coating Germany GmbH) and analyzed with a ZEISS DSM 940 scanning electron microscope 
(ZEISS, Oberkochen, Germany). 
3.3. Fermentation and Production of Extracts 
Strain MF106 was cultured on WSP30 agar plates at 26 °C for 15 days. This pre-culture was used 
for the inoculation of 12 × 2-L Erlenmeyer flasks containing 750 mL WSP30TM medium (1% glucose, 
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0.5% peptone, 0.3% yeast extract, 0.3% malt extract and 3% tropic marine salt (pH = 6.8)) each. After 
incubation for 20 days at 28 °C in the dark as static cultures, extracts of the cultures were obtained. 
The mycelium was separated from the culture broth. One hundred fifty milliliters of ethanol were 
added to the mycelium of each flask and homogenized. After a centrifugation step at 10,000 rpm for  
10 min, the supernatant was collected, and the ethanol was removed by evaporation. The remaining 
aquatic phases of all 12 flasks were combined and extracted twice with 100 mL ethyl acetate. The 
organic phase was used for evaporation. The resulting residue was dissolved in 5 mL methanol to get 
the extract of the mycelium. The fermentation broth was extracted with ethyl acetate (200 mL per each 
flask). One hundred milliliters of deionized water were added to the organic phase. The upper phases 
of all flasks were combined and used for evaporation. The residue was dissolved in 5 mL methanol to 
get the extract of the culture broth. Both extracts were subjected to analytical HPLC-UV/MS. For the 
purification of Compounds 1–3, both extracts were combined. 
3.4. Isolation of Compounds 
The extract was fractionated with the VWR LaPrep HPLC-UV system. Eleven fractions were 
obtained; whereas Fraction 8 contained Compound 1; Fraction 4 contained Compound 2; and Fractions 
6 and 7 contained Compound 3. Fraction 4 and 8 were further purified by the VWR Hitachi Elite 
LaChrom system applying the following parameters for Compound 1 (gradient: 0 min 43% ACN,  
20 min 44% ACN; flow 15 mL/min; UV detection at 261 nm; tR 8.2 min) and for Compound 2 
(gradient: 0 min 34% ACN, 20 min 42% ACN; flow 15 mL/min; UV detection at 210 nm; tR 6.2 min) 
The yields for Compounds 1–3 were 2.3 mg, 1.2 mg and 52.9 mg, respectively. 
Trichodin A (1): brown powder; [α]24D −54 (c 0.1, MeOH); UV (MeOH) λmax (log ε) 202 (4.45),  
232 (4.26) nm; IR νmax: 3105, 2952, 1614, 1547, 1513, 1417, 1263, 1239, 1212, 1043, 894, 830,  
524 cm
−1
; 
1
H NMR and 
13
C NMR, see Table 1; ESIMS m/z 362 [M + Na]
+
; HR-TOF-MS  
m/z 362.1751 [M + Na]
+
 (calcd. for C21H25NNaO3, 362.1727). 
Trichodin B (2): brown powder; [α]24D −46 (c 0.1, MeOH); UV (MeOH) λmax (log ε) 203 (4.30),  
234 (4.21) nm; IR νmax: 3251, 2926, 1639, 1612, 1510, 1435, 1378, 1230, 1042, 833 cm
−1
; 
 
1
H NMR and 
13
C NMR, see Table 1; ESI, MS m/z 494 [M + Na]
+
; HR-TOF-MS m/z 494.2131  
[M + Na]
+
 (calcd. for C26H33NNaO7, 494.2149). 
3.5. Antimicrobial Activity Assays 
The antimicrobial activities of Compounds 1–3 against Bacillus subtilis (DSM 347) and the human 
pathogenic yeast, Candida albicans (DSM 1386), were determined according to Ohlendorf et al. [25]. 
The bioassays using the clinically relevant bacterial strains, Staphylococcus epidermidis (DSM 20044) 
and methicillin-resistant Staphylococcus aureus (MRSA) (DSM 18827) were performed as described 
by Silber et al. [26]. Trichophyton rubrum, a dermatophyte, was tested according to Jansen et al. [27]. 
4. Conclusions 
In addition to the known activities of pyridoxatin, i.e., the inhibition of lipid peroxidation induced 
by free radicals, the inhibition of the hemolysis of rat erythrocytes, the inhibition of the growth of 
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HeLa cells and Candida albicans, which were described by Teshima et al. [9], antimicrobial effects 
against further human pathogenic strains, such as methicillin-resistant Staphylococcus aureus 
(MRSA), were observed in this study. 
This is the first example of a pyridone with a mono sesquiterpene being glycosided. Trichodin A 
and trichodin B are structurally interesting, which would provide opportunities to design and 
synthesize new analogs that could improve the antibiotic activity of these new compounds. 
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